Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders' Equity

v3.21.2
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Series C Preferred Stock
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income / Loss [Member]
Total
Beginning balance, shares at Mar. 31, 2019 2 1,316,335        
Beginning balance, amount at Mar. 31, 2019 $ 0 $ 2 $ 184,074 $ (171,957) $ (4,349) $ 7,770
Cumulative adjustment to April 1, 2017 resulting from adoption of ASU No. 2016-09 (62) (62)
Issuance of common stock, net of offering costs, shares 446,577        
Issuance of common stock, net of offering costs, value 1,376 1,376
Reclassification of stock liability to equity, shares 12,556        
Reclassification of stock liability to equity, value 270 270
Stock based compensation related to issuance of common stock restricted stock grants, shares 2,015        
Stock based compensation related to issuance of common stock restricted stock grants, value     38     38
Stock-based compensation expense, net of forfeitures 801   801
Foreign currency translation adjustment         (1,261) (1,261)
Net loss (3,308) (3,308)
Ending balance, shares at Mar. 31, 2020 2 1,777,483        
Ending balance, amount at Mar. 31, 2020 $ 2 186,559 (175,327) (5,610) 5,624
Adoption of ASC 842
Shares issued in connection with exercise of stock options, shares 93,301        
Shares issued in connection with exercise of stock options, amount 511 511
Shares issued in connection with vesting of restricted stock, shares 3,919        
Shares issued in connection with vesting of restricted stock, amount
Shares issued in connection with exercise of common stock warrants, shares 200,984        
Shares issued in connection with exercise of common stock warrants, amount 1,776 1,776
Shares issued with conversion of C shares, shares 2 17,222        
Shares issued with conversion of C shares, amount
Employee stock-based compensation expense 332 332
Stock based compensation related to issuance of common stock restricted stock grants, value     39     39
Foreign currency translation adjustment         1,031 1,031
Net loss (3,950) (3,950)
Ending balance, shares at Mar. 31, 2021 2,092,909        
Ending balance, amount at Mar. 31, 2021 $ 2 $ 189,217 $ (179,277) $ (4,579) $ 5,363